Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neuropsychiatric, Neurocognitive And Quality Of Life Outcomes In Patients With Epilepsy Treated With Levetiracetam (Keppra) Verses Older AEDs As First Substitution Monotherapy.

Trial Profile

Neuropsychiatric, Neurocognitive And Quality Of Life Outcomes In Patients With Epilepsy Treated With Levetiracetam (Keppra) Verses Older AEDs As First Substitution Monotherapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levetiracetam (Primary) ; Carbamazepine; Valproic acid
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Acronyms KONQUEST

Most Recent Events

  • 03 Sep 2012 The published results stated the original target enrollment in the study was 150.
  • 03 Sep 2012 Status changed from recruiting to completed.
  • 03 Sep 2012 The published results stated that patients were enrolled over a 23-month period from Feb 15 2006 to Dec 23 2008

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top